论文部分内容阅读
目的针对病毒性呼吸道感染患采取重组人干扰素α1b的治疗举措,观察治疗效果情况。方法选取病毒性呼吸道感染患者120例作为研究对象,在患者知情并同意情况下实施分组,分为各具60例患者的研究组以及参照组。将重组人干扰素α1b肌内注射的方式应用于治疗研究组患者中,将利巴韦林静脉滴注治疗方式应用于参照组患者,比较两组效果。结果通过比较咳嗽、气促、啰音消失时间等指标,研究组明显优势于参照组(P<0.05);比较统计的总体治疗有效率,参照组明显低于研究组(P<0.05)。结论将重组人干扰素α1b应用于治疗病毒性呼吸道感染患者的治疗中,能够得到理想的治疗效果。
Objective To investigate the therapeutic effect of recombinant human interferon alb on patients with viral respiratory tract infection. Methods A total of 120 patients with viral respiratory infection were enrolled in this study. Patients were divided into two groups according to their knowledge and consent. They were divided into study group with 60 patients and reference group. The intramuscular injection of recombinant human interferon α1b was applied to patients in the treatment study group, and the ribavirin intravenous drip treatment was applied to the reference group of patients to compare the effects of the two groups. Results Compared with the control group (P <0.05), the study group was significantly superior to the reference group by comparing the indexes of cough, shortness of breath, and disappearance of rales. The total effective rate of treatment was significantly lower in the reference group than in the study group (P <0.05). Conclusion Recombinant human interferon α1b can be used to treat patients with viral respiratory tract infection and can achieve the desired therapeutic effect.